<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>Medical And Surgical Complications</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`üß† Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">Medical And Surgical Complications</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                166 Questions | 664 Total Marks | 176 min Duration | ~63.61 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 166 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 176 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 166</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">Medical And Surgical Complications - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 166</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 166 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "A 30-year-old primigravida woman presents at 29 weeks gestation with headache and a blood pressure of 160/110 mm Hg. Investigations reveal 2+ proteinuria on dipstick, an elevated SGOT and SGPT and a platelet count of 80,000/mm 3 . What is the best management?", "options": [{"label": "A", "text": "Oral antihypertensive therapy", "correct": false}, {"label": "B", "text": "Platelet transfusion", "correct": false}, {"label": "C", "text": "Magnesium sulphate therapy and induction of labour", "correct": true}, {"label": "D", "text": "Intravenous immunoglobulin therapy", "correct": false}], "correct_answer": "C. Magnesium sulphate therapy and induction of labour", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/08/screenshot-2024-01-08-134609.jpg"], "explanation": "<p><strong>Ans. C. Magnesium sulphate therapy and induction of labour</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Ref: Page no 1852, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 1852, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 20-year primi presented at 32 weeks with eclampsia. She was started on MgSO4 (Pritchard‚Äôs regime) and she delivered after induction of labor. Maintenance dose of MgSO4 was continued for 24 hours. Prevention of Mg toxicity involves monitoring of the following clinical parameters:", "options": [{"label": "A", "text": "Deep tendon reflexes, urine output, Respiratory rate", "correct": true}, {"label": "B", "text": "Deep tendon reflexes, O2 saturation, consciousness status", "correct": false}, {"label": "C", "text": "O2 saturation, urine output, heart rate", "correct": false}, {"label": "D", "text": "Heart rate, BP, respiratory rate and urine output", "correct": false}], "correct_answer": "A. Deep tendon reflexes, urine output, Respiratory rate", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A. Deep tendon reflexes, urine output, Respiratory rate</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ The prevention of magnesium toxicity in the management of eclampsia involves careful monitoring of deep tendon reflexes, urine output, and respiratory rate. Deep tendon reflexes help detect early signs of toxicity, urine output indicates renal function and magnesium clearance, and respiratory rate assesses potential respiratory depression from magnesium sulfate.</li><li>‚û§ Ref: page no 439, Textbook of Obstetrics, Dr JB Sharma 1 st edition</li><li>‚û§ Ref: page no 439, Textbook of Obstetrics, Dr JB Sharma 1 st edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 22-year Primigravida presents at 34 weeks to the emergency with a BP of 160/110 mmHg. Her urine albumin is 3 +. She is complaining of headache and blurring of vision. On examination, the fetal heart cannot be auscultated. The uterus is relaxed, and a vaginal examination reveals a soft cervix which is 1 cm dilated and 30% effaced. You administer IV labetalol to lower her BP. What is the best immediate next line of management?", "options": [{"label": "A", "text": "Emergency Cesarean section.", "correct": false}, {"label": "B", "text": "Induction of labor", "correct": false}, {"label": "C", "text": "Prophylactic MgSO4", "correct": true}, {"label": "D", "text": "Urgent Ultrasound to see the fetal status", "correct": false}], "correct_answer": "C. Prophylactic MgSO4", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. Prophylactic MgSO4</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Management of Preeclampsia: Definitive treatment is delivery Mild preeclampsia: Termination at 37 weeks Severe preeclampsia Admit; Consider prophylactic MgSO4 Start anti-hypertensives Terminate at 37 weeks or SOS if Persistent severe HTN Eclampsia, HELLP, pulmonary edema, ARF, DIC Fetal compromise Abruption Pre-viable fetus Steroids (Betamethasone 12 mg 2 doses 24 h apart IM) for lung maturity if < 34 weeks</li><li>‚û§ Management of Preeclampsia:</li><li>‚û§ Definitive treatment is delivery</li><li>‚û§ Mild preeclampsia: Termination at 37 weeks</li><li>‚û§ Severe preeclampsia Admit; Consider prophylactic MgSO4 Start anti-hypertensives Terminate at 37 weeks or SOS if Persistent severe HTN Eclampsia, HELLP, pulmonary edema, ARF, DIC Fetal compromise Abruption Pre-viable fetus</li><li>‚û§ Admit; Consider prophylactic MgSO4 Start anti-hypertensives Terminate at 37 weeks or SOS if Persistent severe HTN Eclampsia, HELLP, pulmonary edema, ARF, DIC Fetal compromise Abruption Pre-viable fetus</li><li>‚û§ Admit; Consider prophylactic MgSO4</li><li>‚û§ Start anti-hypertensives</li><li>‚û§ Terminate at 37 weeks or SOS if Persistent severe HTN</li><li>‚û§ Persistent severe HTN</li><li>‚û§ Persistent severe HTN</li><li>‚û§ Eclampsia, HELLP, pulmonary edema, ARF, DIC</li><li>‚û§ Fetal compromise</li><li>‚û§ Abruption</li><li>‚û§ Pre-viable fetus</li><li>‚û§ Steroids (Betamethasone 12 mg 2 doses 24 h apart IM) for lung maturity if < 34 weeks</li><li>‚û§ Ref: Page no 732, Williams Obstetrics 25 th edition</li><li>‚û§ Ref: Page no 732, Williams Obstetrics 25 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which is NOT an indication of using this drug in obstetrics?", "options": [{"label": "A", "text": "Neuroprotection in preterm labor", "correct": false}, {"label": "B", "text": "Severe preeclampsia", "correct": false}, {"label": "C", "text": "Tocolysis", "correct": false}, {"label": "D", "text": "Severe IUGR", "correct": true}], "correct_answer": "D. Severe IUGR", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/30/picture1.jpg"], "explanation_images": [], "explanation": "<p><strong>Ans. D. Severe IUGR</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ MgSO4 is used for the following obstetric indications.</li><li>‚û§ Eclampsia & severe preeclampsia As a tocolytic in preterm labor For neuroprotection in very preterm</li><li>‚û§ Eclampsia & severe preeclampsia</li><li>‚û§ As a tocolytic in preterm labor</li><li>‚û§ For neuroprotection in very preterm</li><li>‚û§ Ref: page no 439, Textbook of Obstetrics, Dr JB Sharma 1 st edition</li><li>‚û§ Ref: page no 439, Textbook of Obstetrics, Dr JB Sharma 1 st edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "To define preeclampsia, the proteinuria defined is?", "options": [{"label": "A", "text": "‚â• 300 mg/ 24 h", "correct": true}, {"label": "B", "text": "‚â• 30 mg/24 h", "correct": false}, {"label": "C", "text": "‚â• 3 mg/24 h", "correct": false}, {"label": "D", "text": "‚â• 0.3mg/ 24h", "correct": false}], "correct_answer": "A. ‚â• 300 mg/ 24 h", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A. ‚â• 300 mg/ 24 h</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ The diagnosis of preeclampsia involves assessing for the presence of hypertension and significant proteinuria, defined as the excretion of 300 mg or more of protein in a 24-hour urine collection.</li><li>‚û§ Ref: Page no 712, Williams Obstetrics 25 th edition</li><li>‚û§ Ref: Page no 712, Williams Obstetrics 25 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "All are true regarding gestational hypertension except?", "options": [{"label": "A", "text": "The diagnosis is made if BP > 140/90 mmHg after 20 weeks in the absence of proteinuria", "correct": false}, {"label": "B", "text": "10% of eclamptic seizures develop in women with gestational hypertension", "correct": false}, {"label": "C", "text": "The diagnosis is made only if the blood pressure does not return to normal after 12 weeks postpartum", "correct": true}, {"label": "D", "text": "It is also known as transient hypertension as the BP returns to normal postpartum", "correct": false}], "correct_answer": "C. The diagnosis is made only if the blood pressure does not return to normal after 12 weeks postpartum", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/08/screenshot-2024-01-08-184021.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/08/screenshot-2024-01-08-184135.jpg"], "explanation": "<p><strong>Ans. C. The diagnosis is made only if the blood pressure does not return to normal after 12 weeks postpartum</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Ref: page no 711, Williams Obstetrics 25 th edition</li><li>‚û§ Ref: page no 711, Williams Obstetrics 25 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "All are true regarding predictive tests for preeclampsia except?", "options": [{"label": "A", "text": "An exaggerated diastolic notch is seen beyond 24 weeks on uterine artery Doppler in women at risk for developing pre-eclampsia.", "correct": false}, {"label": "B", "text": "A drop in levels of PAPP-A and PlGF is a predictor for preeclampsia.", "correct": false}, {"label": "C", "text": "Angiogenic factors sFlt-1 and s-Eng are decreased in women who are at risk of developing preeclampsia", "correct": true}, {"label": "D", "text": "Cell free DNA is increased in women who are at risk of developing preeclampsia due to accelerated apoptosis of cytotrophoblasts", "correct": false}], "correct_answer": "C. Angiogenic factors sFlt-1 and s-Eng are decreased in women who are at risk of developing preeclampsia", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/08/screenshot-2024-01-08-185956.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/08/screenshot-2024-01-08-190116.jpg"], "explanation": "<p><strong>Ans. C. Angiogenic factors sFlt-1 and s-Eng are decreased in women who are at risk of developing preeclampsia</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Predictors of preeclampsia:</li><li>‚û§ Predictors of preeclampsia:</li><li>‚û§ Biophysical markers : Raised PI in the uterine Artery (11 ‚Äì 14 weeks); notching of uterine Artery waveform (mid trimester). Biochemical markers:</li><li>‚û§ Biophysical markers : Raised PI in the uterine Artery (11 ‚Äì 14 weeks); notching of uterine Artery waveform (mid trimester).</li><li>‚û§ Biophysical markers</li><li>‚û§ Biochemical markers:</li><li>‚û§ Biochemical markers:</li><li>‚û§ S-Flt-1 and s-Eng are Anti-angiogenic factors (Not angiogenic) Roll over test : 28- 32 weeks: BP is measured with patient on her side first and then she is asked to roll on her back and BP is checked again -an increase of 20mmHg in diastolic BP from lateral to supine position is a positive test ‚Äì 30% of such women will develop pre-eclampsia in the future. This test is not done anymore. Angiotensin II sensitivity test : Rise in BP with Angiotensin II infusion.</li><li>‚û§ S-Flt-1 and s-Eng are Anti-angiogenic factors (Not angiogenic)</li><li>‚û§ Anti-angiogenic factors (Not angiogenic)</li><li>‚û§ Roll over test : 28- 32 weeks: BP is measured with patient on her side first and then she is asked to roll on her back and BP is checked again -an increase of 20mmHg in diastolic BP from lateral to supine position is a positive test ‚Äì 30% of such women will develop pre-eclampsia in the future. This test is not done anymore.</li><li>‚û§ Roll over test</li><li>‚û§ Angiotensin II sensitivity test : Rise in BP with Angiotensin II infusion.</li><li>‚û§ Angiotensin II sensitivity test</li><li>‚û§ Ref: Page no 1818, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 1818, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 35-year primigravida is worried about her risk of developing preeclampsia. What intervention would help reduce the risk in her?", "options": [{"label": "A", "text": "Low salt diet", "correct": false}, {"label": "B", "text": "Calcium supplementation started prior to 12 weeks", "correct": false}, {"label": "C", "text": "Aspirin 150 mg/ day prior to 16 weeks", "correct": true}, {"label": "D", "text": "Antioxidants ‚Äì ascorbic acid and Œ±-tocopherol prior to 12 weeks", "correct": false}], "correct_answer": "C. Aspirin 150 mg/ day prior to 16 weeks", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. Aspirin 150 mg/ day prior to 16 weeks</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Low-dose aspirin started before 16 weeks of gestation is a recommended intervention to reduce the risk of developing preeclampsia, particularly for women at high risk.</li><li>‚û§ Low-dose aspirin started before 16 weeks of gestation is a recommended intervention to reduce the risk of developing preeclampsia, particularly for women at high risk.</li><li>‚û§ Ref: Page no 1825, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 1825, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Patellar reflexes disappear when the plasma magnesium level reaches:", "options": [{"label": "A", "text": "8 mEq/L", "correct": false}, {"label": "B", "text": "10 mEq/L", "correct": true}, {"label": "C", "text": "12 mEq/L", "correct": false}, {"label": "D", "text": "14 mEq/L", "correct": false}], "correct_answer": "B. 10 mEq/L", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. 10 mEq/L</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Monitoring for magnesium toxicity is crucial when administering magnesium sulfate, especially in obstetric settings for conditions like preeclampsia or eclampsia. The loss of deep tendon reflexes, such as the patellar reflex, is the first clinical sign and usually occurs at plasma magnesium levels around 10 mEq/L.</li><li>‚û§ Monitoring for magnesium toxicity is crucial when administering magnesium sulfate, especially in obstetric settings for conditions like preeclampsia or eclampsia.</li><li>‚û§ The loss of deep tendon reflexes, such as the patellar reflex, is the first clinical sign and usually occurs at plasma magnesium levels around 10 mEq/L.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 25-year-old P2L2 had just delivered following induction for severe preeclampsia. Her BP on the 2 nd postnatal day is 160/100mmHg. Which anti-hypertensive should be avoided in a breastfeeding mother?", "options": [{"label": "A", "text": "Amlodipine", "correct": true}, {"label": "B", "text": "Labetalol", "correct": false}, {"label": "C", "text": "Captopril", "correct": false}, {"label": "D", "text": "Nifedipine", "correct": false}], "correct_answer": "A. Amlodipine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A. Amlodipine</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Antihypertensive agents with no known adverse effects on infants receiving breast milk: Mnemonic: ECLAM-N Enalapril Captopril Labetalol Atenolol Metoprolol Nifedipine</li><li>‚û§ Antihypertensive agents with no known adverse effects on infants receiving breast milk: Mnemonic: ECLAM-N Enalapril Captopril Labetalol Atenolol Metoprolol Nifedipine</li><li>‚û§ Mnemonic: ECLAM-N</li><li>‚û§ Enalapril Captopril Labetalol Atenolol Metoprolol Nifedipine</li><li>‚û§ Enalapril</li><li>‚û§ Captopril</li><li>‚û§ Labetalol</li><li>‚û§ Atenolol</li><li>‚û§ Metoprolol</li><li>‚û§ Nifedipine</li><li>‚û§ Ref: Smith, M , Waugh, J, Nelson‚ÄêPiercy, C Management of postpartum hypertension The Obstetrician & Gynecologist 2013; 15: 45‚Äì 50</li><li>‚û§ Ref: Smith, M , Waugh, J, Nelson‚ÄêPiercy, C Management of postpartum hypertension The Obstetrician & Gynecologist 2013; 15: 45‚Äì 50</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 37-year lady with chronic hypertension visits the gynecologist for pre-conceptional counselling. She is currently taking Telmisartan for her hypertension. Which is the correct statement?", "options": [{"label": "A", "text": "Stop Telmisartan 3 months prior to conception and re-start it at the 3 rd month of pregnancy", "correct": false}, {"label": "B", "text": "Stop Telmisartan 3 months pre-conceptionally and start Labetalol", "correct": true}, {"label": "C", "text": "Continue Telmisartan", "correct": false}, {"label": "D", "text": "Continue Telmisartan and add Labetalol if BP is uncontrolled in pregnancy", "correct": false}], "correct_answer": "B. Stop Telmisartan 3 months pre-conceptionally and start Labetalol", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Stop Telmisartan 3 months pre-conceptionally and start Labetalol</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ ACE inhibitors and Angiotensin Receptor Blockers (like Telmisartan) cause fetal renal hypoplasia and lead to early onset oligohydramnios as the fetal kidneys are nor formed and are therefore contra-indicated in pregnancy.</li><li>‚û§ ACE inhibitors and Angiotensin Receptor Blockers (like Telmisartan) cause fetal renal hypoplasia and lead to early onset oligohydramnios as the fetal kidneys are nor formed and are therefore contra-indicated in pregnancy.</li><li>‚û§ Ref: Page no 438, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 438, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Anti-hypertensives contra-indicated in pregnancy are all except?", "options": [{"label": "A", "text": "Alpha-methyldopa", "correct": true}, {"label": "B", "text": "Captopril", "correct": false}, {"label": "C", "text": "Enalapril", "correct": false}, {"label": "D", "text": "Losartan", "correct": false}], "correct_answer": "A. Alpha-methyldopa", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A. Alpha-methyldopa</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ The anti-hypertensive drug of choice in pregnancy is labetalol Alpha-methyldopa is considered safe and is one of the preferred anti hypertensives in pregnancy. However, ACE inhibitors (like captopril and enalapril) and ARBs (like losartan) are contraindicated due to their potential adverse effects on the developing fetus.</li><li>‚û§ The anti-hypertensive drug of choice in pregnancy is labetalol</li><li>‚û§ Alpha-methyldopa is considered safe and is one of the preferred anti hypertensives in pregnancy.</li><li>‚û§ However, ACE inhibitors (like captopril and enalapril) and ARBs (like losartan) are contraindicated due to their potential adverse effects on the developing fetus.</li><li>‚û§ Ref: Page no 438, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 438, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "All are regimes of MgSO4 for treatment of eclampsia except?", "options": [{"label": "A", "text": "Dhaka regime", "correct": false}, {"label": "B", "text": "Sibai regime", "correct": false}, {"label": "C", "text": "Magpie regime", "correct": true}, {"label": "D", "text": "Zuspan regime", "correct": false}], "correct_answer": "C. Magpie regime", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. Magpie regime</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ The key educational takeaway is that while there are several recognized regimens for the administration of magnesium sulfate in the management of eclampsia (like the Dhaka, Sibai, and Zuspan regimens), the \"Magpie regime\" is not one of them. Instead, the Magpie Trial was a significant research study that helped establish the effectiveness of magnesium sulfate in this context.</li><li>‚û§ The key educational takeaway is that while there are several recognized regimens for the administration of magnesium sulfate in the management of eclampsia (like the Dhaka, Sibai, and Zuspan regimens), the \"Magpie regime\" is not one of them.</li><li>‚û§ Instead, the Magpie Trial was a significant research study that helped establish the effectiveness of magnesium sulfate in this context.</li><li>‚û§ Ref: page no 439, Textbook of Obstetrics, Dr JB Sharma 1 st edition</li><li>‚û§ Ref: page no 439, Textbook of Obstetrics, Dr JB Sharma 1 st edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "All the following precautions are taken in labor in a woman with pre-eclampsia except?", "options": [{"label": "A", "text": "Cut short the 2 nd stage of labor", "correct": false}, {"label": "B", "text": "Prophylactic methylergometrine at the delivery of anterior shoulder", "correct": true}, {"label": "C", "text": "Restrict IV fluids", "correct": false}, {"label": "D", "text": "Oxytocin 10U IM following delivery", "correct": false}], "correct_answer": "B. Prophylactic methylergometrine at the delivery of anterior shoulder", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. Prophylactic methylergometrine at the delivery of anterior shoulder</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Precautions to be taken in labor in women with pre-eclampsia</li><li>‚û§ Restrict IV fluids to avoid pulmonary edema Cut short 2 nd stage of labor using instrumental delivery Avoid methylergometrine at delivery of anterior shoulder Active management of 3 rd stage of labor including Oxytocin 10IU IM</li><li>‚û§ Restrict IV fluids to avoid pulmonary edema</li><li>‚û§ Cut short 2 nd stage of labor using instrumental delivery</li><li>‚û§ Avoid methylergometrine at delivery of anterior shoulder</li><li>‚û§ Active management of 3 rd stage of labor including Oxytocin 10IU IM</li><li>‚û§ Ref: page no 440, Textbook of Obstetrics, Dr JB Sharma 1 st edition</li><li>‚û§ Ref: page no 440, Textbook of Obstetrics, Dr JB Sharma 1 st edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 32-year-old primigravida at 39 weeks has a BP recording of 150/100 which when repeated is the same. Her baseline BP during earlier visits was 120/80 mmHg. She does not complain of headache/ blurring of vision or epigastric pain. Abdominal exam reveals a term uterus with cephalic presentation and FHR of 140 bpm. Urine albumin is nil. Which is the most likely diagnosis?", "options": [{"label": "A", "text": "Preeclampsia", "correct": false}, {"label": "B", "text": "Chronic hypertension with superimposed preeclampsia", "correct": false}, {"label": "C", "text": "Eclampsia", "correct": false}, {"label": "D", "text": "Gestational hypertension", "correct": true}], "correct_answer": "D. Gestational hypertension", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D. Gestational hypertension</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Ref: page 1780, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: page 1780, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "All of the following indicate superimposed pre-eclampsia in a pregnant female of chronic hypertension except:", "options": [{"label": "A", "text": "New onset proteinuria", "correct": false}, {"label": "B", "text": "Platelet count < 75,000", "correct": false}, {"label": "C", "text": "Increase in systolic BP by 30mm Hg and diastolic by 15 mm Hg", "correct": true}, {"label": "D", "text": "Fresh retinal hypertensive changes", "correct": false}], "correct_answer": "C. Increase in systolic BP by 30mm Hg and diastolic by 15 mm Hg", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/08/screenshot-2024-01-08-192932.jpg", "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/08/screenshot-2024-01-08-193029.jpg"], "explanation": "<p><strong>Ans. C. Increase in systolic BP by 30mm Hg and diastolic by 15 mm Hg</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Ref: Page no 1780, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 1780, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is not a part of HELLP syndrome?", "options": [{"label": "A", "text": "Hemolysis", "correct": false}, {"label": "B", "text": "Elevated liver enzymes", "correct": false}, {"label": "C", "text": "Thrombocytopenia", "correct": false}, {"label": "D", "text": "Retroplacental hemorrhage", "correct": true}], "correct_answer": "D. Retroplacental hemorrhage", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D. Retroplacental hemorrhage</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ HELLP Syndrome</li><li>‚û§ HELLP Syndrome</li><li>‚û§ It is an acronym for Hemolysis (H), Elevated liver enzymes (EL) and Low Platelet count (LP) of < 1,00,000/mm 3 It is a rare complication of pregnancy induced hypertension. It may be associated even with mild hypertension and proteinuria</li><li>‚û§ It is an acronym for Hemolysis (H), Elevated liver enzymes (EL) and Low Platelet count (LP) of < 1,00,000/mm 3</li><li>‚û§ It is a rare complication of pregnancy induced hypertension.</li><li>‚û§ It may be associated even with mild hypertension and proteinuria</li><li>‚û§ Ref: Page no 1849, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 1849, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A multiparous patient who did not attend any antenatal visit and came to causality with complaint of bleeding. On examination uterine tone was increased with BP>144/92 mmHg. Which of the following tests supports the diagnosis of preeclampsia?", "options": [{"label": "A", "text": "Creatinine levels 1.24mg/dl", "correct": true}, {"label": "B", "text": "Platelet counts 154000/microL", "correct": false}, {"label": "C", "text": "Alkaline phosphatase 142 IU/L", "correct": false}, {"label": "D", "text": "Total protein of 252mg in a 24-hour urine collection", "correct": false}], "correct_answer": "A. Creatinine levels 1.24mg/dl", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A. Creatinine levels 1.24mg/dl</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ Preeclampsia Definitions</li><li>‚û§ Preeclampsia</li><li>‚û§ Preeclampsia</li><li>‚û§ Hypertension and proteinuria or In absence of proteinuria, new-onset hypertension with the new onset of any of the following Thrombocytopenia: Platelets <100 x 10 9 /L Renal insufficiency: serum creatinine >1.1 mg/dl or doubling of serum creatinine in the absence of other renal disease Impaired liver function: Elevated blood concentrations of liver transaminases to twice normal concentration Pulmonary edema Neuro: Unexplained new-onset headache unresponsive to medication (without an alternative diagnosis) or visual symptoms</li><li>‚û§ Hypertension and proteinuria or</li><li>‚û§ or</li><li>‚û§ In absence of proteinuria, new-onset hypertension with the new onset of any of the following Thrombocytopenia: Platelets <100 x 10 9 /L Renal insufficiency: serum creatinine >1.1 mg/dl or doubling of serum creatinine in the absence of other renal disease Impaired liver function: Elevated blood concentrations of liver transaminases to twice normal concentration Pulmonary edema Neuro: Unexplained new-onset headache unresponsive to medication (without an alternative diagnosis) or visual symptoms</li><li>‚û§ Thrombocytopenia: Platelets <100 x 10 9 /L Renal insufficiency: serum creatinine >1.1 mg/dl or doubling of serum creatinine in the absence of other renal disease Impaired liver function: Elevated blood concentrations of liver transaminases to twice normal concentration Pulmonary edema Neuro: Unexplained new-onset headache unresponsive to medication (without an alternative diagnosis) or visual symptoms</li><li>‚û§ Thrombocytopenia: Platelets <100 x 10 9 /L</li><li>‚û§ Renal insufficiency: serum creatinine >1.1 mg/dl or doubling of serum creatinine in the absence of other renal disease</li><li>‚û§ Impaired liver function: Elevated blood concentrations of liver transaminases to twice normal concentration</li><li>‚û§ Pulmonary edema</li><li>‚û§ Neuro: Unexplained new-onset headache unresponsive to medication (without an alternative diagnosis) or visual symptoms</li><li>‚û§ or</li><li>‚û§ Preeclampsia with severe features</li><li>‚û§ Preeclampsia with severe features</li><li>‚û§ Preeclampsia diagnosis, above, with any of the following Severe hypertension On two occasions at least 4 hours apart while on bed rest (unless already on antihypertensive therapy) Thrombocytopenia: Platelets <100 x 10 9 /L Impaired liver function (without an alternative diagnosis): Elevated liver transaminases greater than twice upper limit of normal or severe persistent right upper quadrant or epigastric pain not responsive to medications Progressive renal insufficiency: serum creatinine >1.1 mg/dl or doubling of serum creatinine in the absence of other renal disease Pulmonary edema Neuro: Unexplained new-onset headache unresponsive to medication (without an alternative diagnosis) or visual symptoms</li><li>‚û§ Preeclampsia diagnosis, above, with any of the following Severe hypertension On two occasions at least 4 hours apart while on bed rest (unless already on antihypertensive therapy) Thrombocytopenia: Platelets <100 x 10 9 /L Impaired liver function (without an alternative diagnosis): Elevated liver transaminases greater than twice upper limit of normal or severe persistent right upper quadrant or epigastric pain not responsive to medications Progressive renal insufficiency: serum creatinine >1.1 mg/dl or doubling of serum creatinine in the absence of other renal disease Pulmonary edema Neuro: Unexplained new-onset headache unresponsive to medication (without an alternative diagnosis) or visual symptoms</li><li>‚û§ Severe hypertension On two occasions at least 4 hours apart while on bed rest (unless already on antihypertensive therapy) Thrombocytopenia: Platelets <100 x 10 9 /L Impaired liver function (without an alternative diagnosis): Elevated liver transaminases greater than twice upper limit of normal or severe persistent right upper quadrant or epigastric pain not responsive to medications Progressive renal insufficiency: serum creatinine >1.1 mg/dl or doubling of serum creatinine in the absence of other renal disease Pulmonary edema Neuro: Unexplained new-onset headache unresponsive to medication (without an alternative diagnosis) or visual symptoms</li><li>‚û§ Severe hypertension On two occasions at least 4 hours apart while on bed rest (unless already on antihypertensive therapy)</li><li>‚û§ On two occasions at least 4 hours apart while on bed rest (unless already on antihypertensive therapy)</li><li>‚û§ On two occasions at least 4 hours apart while on bed rest (unless already on antihypertensive therapy)</li><li>‚û§ Thrombocytopenia: Platelets <100 x 10 9 /L</li><li>‚û§ Impaired liver function (without an alternative diagnosis): Elevated liver transaminases greater than twice upper limit of normal or severe persistent right upper quadrant or epigastric pain not responsive to medications</li><li>‚û§ or</li><li>‚û§ or</li><li>‚û§ Progressive renal insufficiency: serum creatinine >1.1 mg/dl or doubling of serum creatinine in the absence of other renal disease</li><li>‚û§ Pulmonary edema</li><li>‚û§ Neuro: Unexplained new-onset headache unresponsive to medication (without an alternative diagnosis) or visual symptoms</li><li>‚û§ or</li><li>‚û§ Note: The following are not diagnostic criteria for the diagnosis of preeclampsia or preeclampsia with severe features</li><li>‚û§ Note:</li><li>‚û§ Clinically evident edema Rapid weight gain Massive proteinuria Does not qualify as a ‚Äòsevere feature‚Äô Fetal growth restriction Expectant management ‚Äòmay be reasonable‚Äô if mother and fetus appear stable and no other clinical indication is present that would indicate the need for early delivery ACOG states that while it is important to monitor fetal status, FGR in the setting of all other fetal assessment being within normal limits (e.g., AFV, Doppler) Uric acid Hyperuricemia in hypertensive pregnancy is not a diagnostic marker, but is an important finding as a risk factor for adverse maternal and fetal outcomes Small for gestational age (SGA) infant Prematurity Risk for adverse maternal outcomes if include patients with preeclampsia and risks increase with increasing concentration of uric acid May be warranted in the setting of ‚Äòdiagnostic dilemmas‚Äô such as diagnosing superimposed preeclampsia in the setting of chronic hypertension</li><li>‚û§ Clinically evident edema</li><li>‚û§ Rapid weight gain</li><li>‚û§ Massive proteinuria Does not qualify as a ‚Äòsevere feature‚Äô</li><li>‚û§ Does not qualify as a ‚Äòsevere feature‚Äô</li><li>‚û§ Does not qualify as a ‚Äòsevere feature‚Äô</li><li>‚û§ Fetal growth restriction Expectant management ‚Äòmay be reasonable‚Äô if mother and fetus appear stable and no other clinical indication is present that would indicate the need for early delivery ACOG states that while it is important to monitor fetal status, FGR in the setting of all other fetal assessment being within normal limits (e.g., AFV, Doppler)</li><li>‚û§ Expectant management ‚Äòmay be reasonable‚Äô if mother and fetus appear stable and no other clinical indication is present that would indicate the need for early delivery ACOG states that while it is important to monitor fetal status, FGR in the setting of all other fetal assessment being within normal limits (e.g., AFV, Doppler)</li><li>‚û§ Expectant management ‚Äòmay be reasonable‚Äô if mother and fetus appear stable and no other clinical indication is present that would indicate the need for early delivery ACOG states that while it is important to monitor fetal status, FGR in the setting of all other fetal assessment being within normal limits (e.g., AFV, Doppler)</li><li>‚û§ Uric acid Hyperuricemia in hypertensive pregnancy is not a diagnostic marker, but is an important finding as a risk factor for adverse maternal and fetal outcomes Small for gestational age (SGA) infant Prematurity Risk for adverse maternal outcomes if include patients with preeclampsia and risks increase with increasing concentration of uric acid May be warranted in the setting of ‚Äòdiagnostic dilemmas‚Äô such as diagnosing superimposed preeclampsia in the setting of chronic hypertension</li><li>‚û§ Hyperuricemia in hypertensive pregnancy is not a diagnostic marker, but is an important finding as a risk factor for adverse maternal and fetal outcomes Small for gestational age (SGA) infant Prematurity Risk for adverse maternal outcomes if include patients with preeclampsia and risks increase with increasing concentration of uric acid May be warranted in the setting of ‚Äòdiagnostic dilemmas‚Äô such as diagnosing superimposed preeclampsia in the setting of chronic hypertension</li><li>‚û§ Hyperuricemia in hypertensive pregnancy is not a diagnostic marker, but is an important finding as a risk factor for adverse maternal and fetal outcomes Small for gestational age (SGA) infant Prematurity Risk for adverse maternal outcomes if include patients with preeclampsia and risks increase with increasing concentration of uric acid</li><li>‚û§ Small for gestational age (SGA) infant Prematurity Risk for adverse maternal outcomes if include patients with preeclampsia and risks increase with increasing concentration of uric acid</li><li>‚û§ Small for gestational age (SGA) infant</li><li>‚û§ Prematurity</li><li>‚û§ Risk for adverse maternal outcomes if include patients with preeclampsia and risks increase with increasing concentration of uric acid</li><li>‚û§ May be warranted in the setting of ‚Äòdiagnostic dilemmas‚Äô such as diagnosing superimposed preeclampsia in the setting of chronic hypertension</li><li>‚û§ Ref: https://www.preeclampsia.org/frontend/assets/img/advocacy_resource/Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin,_Number_222_1605448006.pdf</li><li>‚û§ Ref:</li><li>‚û§ https://www.preeclampsia.org/frontend/assets/img/advocacy_resource/Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin,_Number_222_1605448006.pdf</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 36-year primigravida presents with seizures to the emergency. On examination, she is 36 weeks pregnant with BP 150/100mmHg. She is given loading dose of MGSO4 as per Pritchards regime but has another seizure. Which of the following should be done next?", "options": [{"label": "A", "text": "Midazolam", "correct": false}, {"label": "B", "text": "Thiopental", "correct": false}, {"label": "C", "text": "Additional magnesium sulphate", "correct": true}, {"label": "D", "text": "All of the above", "correct": false}], "correct_answer": "C. Additional magnesium sulphate", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/30/picture2.jpg"], "explanation_images": [], "explanation": "<p><strong>Ans. C. Additional magnesium sulphate</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Short acting benzodiazepines like midazolam may be used to control the ongoing seizure. Consider thiopental if the seizures are refractory. Ensure that the patient is also receiving the maintenance dose of magnesium sulfate to prevent further seizures.</li><li>‚û§ Short acting benzodiazepines like midazolam may be used to control the ongoing seizure.</li><li>‚û§ Consider thiopental if the seizures are refractory.</li><li>‚û§ Ensure that the patient is also receiving the maintenance dose of magnesium sulfate to prevent further seizures.</li><li>‚û§ Ref: Page no 1862, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 1862, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Preeclampsia is a marker for all of the following morbidities later in life except?", "options": [{"label": "A", "text": "Chronic renal disease", "correct": false}, {"label": "B", "text": "Ischemic heart disease", "correct": false}, {"label": "C", "text": "Metabolic syndrome", "correct": false}, {"label": "D", "text": "Non- Alcoholic steatohepatitis", "correct": true}], "correct_answer": "D. Non- Alcoholic steatohepatitis", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D. Non-Alcoholic Steatohepatitis</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective</li><li>‚û§ LONG TERM CONSEQUENCES ASSOCIATED WITH PREECLAMPSIA:</li><li>‚û§ LONG TERM CONSEQUENCES ASSOCIATED WITH PREECLAMPSIA:</li><li>‚û§ The earlier preeclampsia is diagnosed during the index pregnancy, the greater the likelihood of recurrence. Nulliparous diagnosed with preeclampsia before 30 weeks have a recurrence risk as high as 40 percent during a subsequent pregnancy. Women with HELLP have risk of 5 to 26 percent risk of recurrence in subsequent pregnancy 20 percent of preeclampsia women had hypertension at interval of 2 years. Ischemic heart disease Stroke Increased risk of chronic hypertension and diabetes and even metabolic syndrome 4-fold increased risk of chronic renal disease Increased risk of impaired cognitive functioning and lower vision related quality of life</li><li>‚û§ The earlier preeclampsia is diagnosed during the index pregnancy, the greater the likelihood of recurrence. Nulliparous diagnosed with preeclampsia before 30 weeks have a recurrence risk as high as 40 percent during a subsequent pregnancy.</li><li>‚û§ Women with HELLP have risk of 5 to 26 percent risk of recurrence in subsequent pregnancy</li><li>‚û§ 20 percent of preeclampsia women had hypertension at interval of 2 years.</li><li>‚û§ Ischemic heart disease</li><li>‚û§ Stroke</li><li>‚û§ Increased risk of chronic hypertension and diabetes and even metabolic syndrome</li><li>‚û§ 4-fold increased risk of chronic renal disease</li><li>‚û§ Increased risk of impaired cognitive functioning and lower vision related quality of life</li><li>‚û§ Ref: Page 1880, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page 1880, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A Primigravida presents at 32 weeks with pre-eclampsia. She complains of decreased fetal movements. An umbilical artery Doppler is done which is as shown in the image. What is the next best step in management?", "options": [{"label": "A", "text": "Conservative management with anti-hypertensives", "correct": false}, {"label": "B", "text": "Delivery after 34 weeks of gestation", "correct": false}, {"label": "C", "text": "Immediate delivery", "correct": true}, {"label": "D", "text": "Declare fetal demise", "correct": false}], "correct_answer": "C. Immediate delivery", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/30/picture3.jpg"], "explanation_images": [], "explanation": "<p><strong>Ans. C. Immediate delivery</strong></p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following are feature(s) of magnesium toxicity in pregnancy? Loss of deep tendon reflex Decreased respiratory rate Decreased urine output Hypertension Increased heart rate", "options": [{"label": "A", "text": "a, b, c", "correct": false}, {"label": "B", "text": "a, d, e", "correct": false}, {"label": "C", "text": "a, b", "correct": true}, {"label": "D", "text": "a, b, c, d", "correct": false}], "correct_answer": "C. a, b", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. a, b</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Features of Magnesium Toxicity:</li><li>‚û§ Features of Magnesium Toxicity:</li><li>‚û§ Loss of deep tendon reflex (Depression of patellar reflex is the earliest sign of patellar toxicity): Earliest Sign Decreased respiratory rate (<12 per minute) Chest pain, heart block, pulmonary edema Cardiac arrest O 2 saturation monitoring (PaO2 < 95%) Double vision Slurred speech Nausea-vomiting Muscular weakness</li><li>‚û§ Loss of deep tendon reflex (Depression of patellar reflex is the earliest sign of patellar toxicity): Earliest Sign</li><li>‚û§ Decreased respiratory rate (<12 per minute)</li><li>‚û§ Chest pain, heart block, pulmonary edema</li><li>‚û§ Cardiac arrest</li><li>‚û§ O 2 saturation monitoring (PaO2 < 95%)</li><li>‚û§ Double vision</li><li>‚û§ Slurred speech</li><li>‚û§ Nausea-vomiting</li><li>‚û§ Muscular weakness</li><li>‚û§ **Decreased urine output is not a feature of Mg toxicity. Renal failure can be seen in severe preeclampsia/ eclampsia and as Mg is excreted through the kidneys, decreased renal function can increase the Mg levels in the blood thereby leading to Mg toxicity.</li><li>‚û§ Ref: Page no 1880, Williams Obstetrics 26 th edition</li><li>‚û§ Ref: Page no 1880, Williams Obstetrics 26 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 34-year Primigravida presents to the antenatal OPD. Her mother is a diabetic and she is screened for Diabetes at her 8 weeks antenatal visit. What was the most likely screening method used?", "options": [{"label": "A", "text": "FBS & PPBS", "correct": false}, {"label": "B", "text": "HBA1C", "correct": true}, {"label": "C", "text": "Urine routine for sugar", "correct": false}, {"label": "D", "text": "GCT", "correct": false}], "correct_answer": "B. HBA1C", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B. HBA1C</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective (Summary):</li><li>‚û§ Hemoglobin A1C (HBA1C) is the most likely screening method used for diabetes at the 8-week antenatal visit, especially when there is a family history of diabetes. It provides a longer-term view of blood sugar control.</li><li>‚û§ Ref: Page 1108, Williams Obstetrics 25 th edition</li><li>‚û§ Ref: Page 1108, Williams Obstetrics 25 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "During a routine antenatal visit, an 24-year G1 at 20 weeks gestational age undergoes a urinalysis. The dipstick done indicates the presence of glycosuria. All other parameters of the urine test are normal. Which of the following is the most likely etiology of sugar detected in the urine?", "options": [{"label": "A", "text": "The patient has diabetes", "correct": false}, {"label": "B", "text": "The patient has a urine infection", "correct": false}, {"label": "C", "text": "The patient‚Äôs urinalysis is consistent with normal pregnancy", "correct": true}, {"label": "D", "text": "The patient‚Äôs urine sample is contaminated.", "correct": false}], "correct_answer": "C. The patient‚Äôs urinalysis is consistent with normal pregnancy", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C. The patient‚Äôs urinalysis is consistent with normal pregnancy</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ Physiological glycosuria, a normal response to hormonal changes in pregnancy, may lead to the presence of glucose in the urine without underlying diabetes. It is essential to consider other factors, such as diabetes, urinary tract infections, and sample contamination, and perform further tests if necessary to determine the cause of glycosuria.</li><li>‚û§ Physiological glycosuria, a normal response to hormonal changes in pregnancy, may lead to the presence of glucose in the urine without underlying diabetes. It is essential to consider other factors, such as diabetes, urinary tract infections, and sample contamination, and perform further tests if necessary to determine the cause of glycosuria.</li><li>‚û§ Ref: Page 66, William‚Äôs Obstetrics 25 th edition</li><li>‚û§ Ref: Page 66, William‚Äôs Obstetrics 25 th edition</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "An infant was born at 36 weeks of pregnancy with a birthweight 4.5 kg as shown in the image. Which of the following conditions is associated with this presentation?", "options": [{"label": "A", "text": "Anemia", "correct": false}, {"label": "B", "text": "Antepartum hemorrhage", "correct": false}, {"label": "C", "text": "Gestational Diabetes mellitus", "correct": true}, {"label": "D", "text": "Thrombocytopenia", "correct": false}], "correct_answer": "C. Gestational Diabetes mellitus", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/15/picture13_fMnCKOd.jpg"], "explanation_images": [], "explanation": "<p><strong>Ans. C. Gestational Diabetes mellitus</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ The birth of an infant with a birthweight of 4.5 kg at 36 weeks of pregnancy is suggestive of macrosomia. Macrosomia is commonly associated with maternal gestational diabetes mellitus (GDM), which can lead to larger birthweights in babies.</li><li>‚û§ The birth of an infant with a birthweight of 4.5 kg at 36 weeks of pregnancy is suggestive of macrosomia.</li><li>‚û§ Macrosomia is commonly associated with maternal gestational diabetes mellitus (GDM), which can lead to larger birthweights in babies.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "For diagnosis of overt gestational diabetes, the fasting blood sugar (FBS] level should be?", "options": [{"label": "A", "text": "‚â• 110 mg/dl", "correct": false}, {"label": "B", "text": "‚â• 126 mg/dl", "correct": true}, {"label": "C", "text": "‚â• 140 mg/dl", "correct": false}, {"label": "D", "text": "‚â• 200 mg/dl", "correct": false}], "correct_answer": "B. ‚â• 126 mg/dl", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/15/screenshot-2024-01-15-200643.jpg"], "explanation": "<p><strong>Ans. B. ‚â• 126 mg/dl</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>‚û§ Educational Objective:</li><li>‚û§ To diagnose overt gestational diabetes, the fasting blood sugar (FBS) level should be ‚â• 126 mg/dl (milligrams per decilitre).</li><li>‚û§ To diagnose overt gestational diabetes, the fasting blood sugar (FBS) level should be ‚â• 126 mg/dl (milligrams per decilitre).</li><li>‚û§ It